Why the study?
Does clentiazem prevent calcium overload and improve functional recovery in isolated ferret hearts subjected to ischemia and reperfusion?
Does clentiazem prevent calcium overload and improve functional recovery in isolated ferret hearts subjected to ischemia and reperfusion?
The cardioprotective effect of clentiazem against ischemia-reperfusion injury requires the reduction of calcium entry from the extracellular space, as reflected by its negative inotropic effect during pretreatment.
Answers are grounded in this paper and cite their sources.
Negative inotropy appears necessary for clentiazem cardioprotection in isolated hearts; leaves open clinical translation.
To elucidate whether or not Ca channel blockers have an intrinsic benefit that cannot be attributed to the reduction of Ca2+ entry by pretreatment, time-averaged intracellular Ca2+ concentration ([Ca2+]i) and energy-related phosphates were measured in isolated ferret hearts using nuclear magnetic resonance. In the drug-free ischemic group, [Ca2+]i increased significantly during 30 min of global ischemia at 30 degrees C and during 0-5 min of reperfusion. After 30 min of reperfusion, isovolumic left ventricular developed pressure recovered only to 63+/-7% of the pre-ischemic level (mean+/-SEM; N=5). Pretreatment with the Ca channel blocker clentiazem (10(-7) mol/L) itself depressed developed pressure by 53+/-9%. In the clentiazem group, [Ca2+]i showed no significant changes during ischemia or reperfusion. Recovery of developed pressure (87+/-8% of untreated level) was significantly higher than in the non-treated group (p<0.05). Nevertheless, when the negative inotropism of clentiazem was offset by increasing [Ca]o from 2 to 3 mmol/L, no beneficial effects of clentiazem were observed; [Ca2+]i increased significantly during 0-5 min of reperfusion, and developed pressure recovered only 60+/-7% of untreated level. These results indicate that reduction of Ca2+ entry from the extracellular space to the myocyte, as reflected by negative inotropism during pretreatment, is required for clentiazem to protect myocardium in a model of global ischemia and reperfusion.
No takes yet. Share an insight, caveat, or question.
Kusuoka et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: